美国血液学年会（ASH）成立于1958年，是全球最大的关于血液疾病病因及治疗的专业协会，其使命在于促进血液病研究及诊治水平的提升。2022年12月10日~13日，第64届ASH即将在美国路易斯安那州新奥尔良召开。ASH官网最新公布了入选今年大会的6个LBA（Late-Breaking Abstracts），其具体内容将于12月13日美东时间星期二上午09:00-10:30展现。作为血液学首屈一指的交流盛会，每年的ASH大会都会带来最前沿的血液学研究内容。让我们先看看今年入选LBA的研究，一起一睹为快吧！具体LBA详情，请关注【肿瘤资讯】后续报道。
【LBA1】随机、III期ECOG-ACRIN E1910研究：Blinatumomab 巩固治疗改善了新诊断的具有可测量残留病灶阴性缓解的 B 系急性淋巴细胞白血病成人患者的总生存期！
题目：Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
汇报人：Mark R. Litzow
汇报时间：2022 年 12 月 13 日，星期二，上午 9:00 至上午 10:30
【LBA2】随机、活性对照、开放标签、III期Apply-PNH研究：口服Iptacopan（一种近端B因子补体抑制剂）单药治疗阵发性夜间血红蛋白尿和残余贫血患者的疗效和安全性优于静脉输注Eculizumab或Ravulizumab（末端补体抑制剂）
题目：Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
汇报人：Regis Peffault De Latour
汇报时间：2022 年 12 月 13 日，星期二，上午 9:00 至上午 10:30
【LBA-3】国际、随机、III期MATRix/IELSG43研究：非清髓性化学免疫治疗 vs 大剂量化疗序贯自体干细胞移植 (HDC-ASCT) 巩固治疗对原发性 CNS 淋巴瘤患者生存期的影响
题目：Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
汇报人：Gerald Illerhau
汇报时间：2022年 12 月 13 日，星期二，上午 9:00 至上午 10:30
【LBA4】：III期BMT CTN 1703研究： 低强度预处理条件下，移植后环磷酰胺、他克莫司和霉酚酸酯作为移植物抗宿主病 (GVHD) 预防治疗的新标准
题目：Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703
汇报人：Shernan G Holta
汇报时间：2022 年 12 月 13 日，星期二，上午 9:00 至上午 10:30
【LBA5】低分子量肝素 vs 标准妊娠护理治疗复发性流产和遗传性易栓症妇女 (ALIFE2)：一项开放标签、III期随机对照试验
题目：Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial
汇报人：Saskia Middeldorp
汇报时间：2022 年 12 月 13 日，星期二，上午 9:00 至上午 10:30
【LBA-6】随机、III 期ALPINE研究最终分析：泽布替尼治疗复发/难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤(R/R CLL/SLL)的无进展生存期 (PFS) 优于伊布替尼
题目：Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
汇报人：Jennifer R. Brown
汇报时间：2022 年 12 月 13 日，星期二，上午 9:00 至上午 10:30
1. Mark R. Litzow, et al. Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial . 2022ASH. LAB1
2. Regis Peffault De Latour, et al. Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study . 2022ASH. LAB2
3. Gerald Illerhau, et al. Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43). 2022ASH. LAB3
4. Shernan G Holta, et al. Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703 . 2022ASH. LAB4
5. Saskia Middeldorp, et al. Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial . 2022ASH. LAB5
6. Jennifer R. Brown, et al. Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study . 2022ASH. LAB6
排版编辑：Luna
苏公网安备32059002004080号
